

## PLOS ONE

# 1 High prevalence and risk factors of transmission of hepatitis delta virus in 2 pregnant women in the Center Region of Cameroon

3  
4 Juliette-Laure Ndzie Ondigui<sup>1,2</sup>, Email : [njulielaure@gmail.com](mailto:njulielaure@gmail.com)

5 Nadège Mafopa Goumkwa<sup>2</sup>, Email : [g.m.nadege@gmail.com](mailto:g.m.nadege@gmail.com)

6 Cindy Lobe<sup>2,3</sup>, Email: [lobecindy@hotmail.com](mailto:lobecindy@hotmail.com)

7 Brigitte Wandji<sup>4</sup>, Email: [wandji.brigitte@yahoo.com](mailto:wandji.brigitte@yahoo.com)

8 Patrick Awoumou<sup>5,2</sup>, Email: [patrick26lebon@gmail.com](mailto:patrick26lebon@gmail.com)

9 Prisca Voussou Djivida<sup>5</sup>, Email : [djividaprisca@yahoo.fr](mailto:djividaprisca@yahoo.fr)

10 Puinta Peyonga<sup>5</sup>, Email : [puiPEN@yahoo.com](mailto:puiPEN@yahoo.com)

11 Solange Manju Atah<sup>6</sup> Email : [solangeneh36@gmail.com](mailto:solangeneh36@gmail.com)

12 Vivian Verbe<sup>7</sup>, Email : [visale@yahoo.com](mailto:visale@yahoo.com)

13 Rachel Kamgaing Simo<sup>2</sup>, Email: [r.kamgaing@yahoo.it](mailto:r.kamgaing@yahoo.it)

14 Sylvie Agnès Moudourou<sup>2</sup>, Email : [sylvie.moudourou@gmail.com](mailto:sylvie.moudourou@gmail.com)

15 Ana Gutierrez<sup>9</sup>, Email : [anagutiaci@yahoo.es](mailto:anagutiaci@yahoo.es)

16 Rosi Garcia<sup>9</sup>, Email : [rosi.acibikop@gmail.com](mailto:rosi.acibikop@gmail.com)

17 Isabelle Fernandez<sup>9</sup>, Email : [i.fernandez@esclavasaci.es](mailto:i.fernandez@esclavasaci.es)

18 Sara Honorine Riwom Essama<sup>1</sup>, Email : [sarariwom@yahoo.fr](mailto:sarariwom@yahoo.fr)

19 Robinson Mbu<sup>4,10</sup>, Email : [robinsonmbu@gmail.com](mailto:robinsonmbu@gmail.com)

20 Judith Torimiro<sup>2, 5\*</sup>, Email: [jn.torimiro@gmail.com](mailto:jn.torimiro@gmail.com)

21  
22 *1-Department of Microbiology, Faculty of Sciences, University of Yaoundé 1, Yaounde,*  
23 *Cameroon;*

24 *2- “Chantal BIYA” International Reference Center for research on HIV/AIDS prevention and*  
25 *management (CIRCB), Yaounde, Cameroon;*

26 *3- Department of Food Science and Nutrition, National School of Agro-Industrial Sciences,*  
27 *University of Ngaoundere, Ngaoundere, Cameroon;*

28 *4- Yaoundé Gynecology Obstetrics and Paediatrics Hospital, Yaounde, Cameroon;*

29 *5- Department of Biochemistry, Faculty of Medicine and Biomedical Sciences, University of*  
30 *Yaounde 1, Yaounde, Cameroon;*

31 *6- Department of Public Health, Faculty of Medicine and Biomedical Sciences, University of*  
32 *Yaounde 1, Yaounde, Cameroon;*

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## PLOS ONE

33 7-Cité Verte District Hospital, Yaounde, Cameroon;

34 8- Biyem-Assi District Hospital, Yaounde, Cameroon

35 9- Bikop Catholic Health Center, Bikop, Cameroon

36 10- Department of Gynecology/Obstetrics, Faculty of Medicine and Biomedical Sciences,  
37 University of Yaounde 1, Yaounde, Cameroon

### 38 **Authors Contributions**

39 *Designed the study:* Judith Torimiro, Robinson Mbu, Sara Honorine Riwom Essama, Juliette-  
40 Laure Ndzie Ondigui; *Collected the data:* Judith Torimiro, Juliette-Laure Ndzie Ondigui,  
41 Brigitte Wandji, Patrick Awoumou, Puinta Peyong, Prisca Voussou Djivida, Vivian Verbe,  
42 Eveline Tincho Fogueu, Rachel Kamgaing Simo, Sylvie Agnès Moudourou , Ana Gutierrez ,  
43 Rosi Garcia, Isabelle Fernandez; *Analyzed and interpreted the data:* Juliette-Laure Ndzie  
44 Ondigui, Nadège Mafopa Goumkwa, Cindy Lobe, Judith Torimiro; *Initiated and drafted the*  
45 *manuscript:* Juliette-Laure Ndzie Ondigui, Nadège Mafopa Goumkwa, Judith Torimiro;  
46 *Revised the manuscript:* all the authors read and approved the final manuscript.

### 47 **\*Corresponding author:**

48 Judith Torimiro

49 Email: [jn.torimiro@gmail.com](mailto:jn.torimiro@gmail.com)

50

51

52

53

54

55

56

57

58

59

60

61

62

63

## PLOS ONE

### 64 ABSTRACT

65 **Background:** Hepatitis B virus (HBV) and hepatitis delta virus (HDV) co-infection has been  
66 described as the most severe form of viral hepatitis, and both can be co-transmitted from  
67 mother-to-child. A seroprevalence of 4.0% of HDV infection was reported in pregnant women  
68 in Yaoundé, and 11.9% in the general population in Cameroon. Our objective was to describe  
69 the rate of HDV infection in pregnant women and to determine risk factors associated with  
70 mother-to-child transmission of HDV.

71 **Materials and Methods:** A cross-sectional, descriptive study was conducted from January  
72 2019 to July 2022 among pregnant women attending antenatal contacts in seven health  
73 structures in the Centre Region of Cameroon. A consecutive sampling (non-probability  
74 sampling) was used to select only women of age over 21 years, who gave a written informed  
75 consent. Following an informed consent, an open-ended questionnaire was used for a  
76 Knowledge, Attitude and Practice (KAP) survey of these women, and their blood specimens  
77 collected and were screened for HBsAg, anti-HIV and anti-HCV antibodies by rapid tests and  
78 ELISA. HBsAg-positive samples were further screened for HBeAg, anti-HDV, anti-HBs, and  
79 anti HBc antibodies by ELISA, and plasma HDV RNA load measured by RT-qPCR.

80 **Results:** Of 1992 pregnant women, a rate of 6.7% of HBsAg (134/1992) with highest rate in  
81 the rural areas, and 3.9% of hepatitis vaccination rate were recorded. Of 134, 44 (32.3%) were  
82 anti-HDV antibody-positive, and 47.6% had detectable RNA viraemia. Two women of 44 anti-  
83 HDV-positive cases (4.5%) were co-infected with HBV and HCV, while 5 (11.4%) with HIV  
84 and HBV. Multiple deliveries, the presence of tattoos and/or scarifications were significantly  
85 statistically associated with the presence of anti-HDV antibodies. Of note, 80% of women with  
86 negative HBeAg and positive anti-HBe serological profile, had plasma HDV RNA load of more  
87 than log 3.25 (>10.000 copies/ml).

### 88 Conclusion

89 These results show an intermediate rate of HDV infection among pregnant women with high  
90 level of HDV RNA viremia, which suggest an increased risk of vertical and horizontal co-  
91 transmission of HDV.

92

93 **Keywords:** risk factors, transmission, hepatitis delta virus, pregnancy

## PLOS ONE

### 94 **Introduction**

95 Hepatitis B virus (HBV) is the aetiologic agent of hepatitis B. The WHO estimates that 296  
96 million people were living with chronic hepatitis B in 2019 with 1.5 million new infections  
97 each year[1], whereas Hepatitis delta virus (HDV) affects nearly 5% of people with chronic  
98 hepatitis B worldwide[1]. HDV requires the presence of HBV in order to replicate [2-4] in co-  
99 infection or super-infection causing the most serious form of chronic viral hepatitis, given its  
100 more rapid progression to hepatocellular carcinoma and death [5-8]. It is also worth noting, the  
101 low HBV vaccination rate among pregnant women in Cameroon of less than 2.5% [9].

102 HBV and HDV can be transmitted through skin lesions (injection, scarification, tattooing),  
103 contact with infected blood or blood products, but mostly they are co-transmitted through sexual  
104 intercourse and from mother-to-child [10]. Therefore, pregnant women are an index population  
105 for both vertical and horizontal transmission of HBV and HDV. However, certain practices  
106 favour the transmission of HBV in the Centre Region of Cameroon. They include poor  
107 accessibility to healthcare, low rate of vaccination, cultural and traditional beliefs, low rate of  
108 condom use, high rate of early age of first sexual intercourse, low rate of official marriage, high  
109 rate of home delivery, poor link to prevention of mother-to-child transmission (PMTCT)  
110 activities, and to other maternal-infant disease prevention efforts in Cameroon.

111 HBV/HDV co-transmission from mother-to-child has been described [11, 12]. It is an event  
112 that seems rare but remains possible and the risk could increase with high level of plasma load  
113 of HBV DNA and HDV RNA in the pregnant woman [13-15], in individuals with multiple  
114 sexual partners and/or with scarification [16]. Vaccination against hepatitis B is an effective  
115 strategy to prevent HDV infection. Therefore, scaling-up the national vaccination programme  
116 against hepatitis B in the general population, could lead to a drop in the incidence of hepatitis  
117 D worldwide. In 2018, it was reported that 83.3% of pregnant women attending ANC in  
118 Yaounde, Cameroon, knew that vaccination against HBV infection is a method of prevention,  
119 and 47.1% knew that HBV could be transmitted from mother-to-child. However, only 2.5%  
120 had received three doses of the hepatitis B vaccine [9, 17]. In Cameroon the seroprevalence of  
121 HBV (HBsAg) in the general population is 11.2%, about two to three times higher than that of  
122 the human immunodeficiency virus (HIV) of 3.4% [18, 19]. In 2021, the Cameroon Ministry  
123 of Public Health reported a seroprevalence among pregnant women at first trimester of 5.0% in  
124 the Centre Region where this study was carried out against 8.63% of national prevalence [20].  
125 In addition, in Central Africa, HDV seroprevalence is estimated at 25.64% in the general  
126 population [7], compared to 46.73% in Cameroon in 2018 [21].

## **PLOS ONE**

127 Low hepatitis B vaccination coverage in the sexually active population, and lack of recent  
128 epidemiological data on HDV in pregnant women, show that the general population in  
129 Cameroon is at risk of continuous spread of HBV and HDV from mother-to-child and  
130 horizontally. Thus, our specific objectives were to determine the rates of HDV infection and  
131 factors associated with risk of HDV infection among pregnant women.

### **132 Materials and methods**

#### **133 Study design, enrollment procedure and eligibility criteria**

134 A cross-sectional study was conducted from January 2019 to July 2022 in a tertiary hospital,  
135 five District hospitals, and one rural Health Center in the Center Region of Cameroon, among  
136 pregnant women attending ANC. A total of 1992 pregnant women of age over 21 years were  
137 enrolled (Figure 1) from an anticipated 1475 participants deduced from a statistical formula  
138 shown below [22] which is commonly used to determine the minimum sample size in medical  
139 studies:

$$140 \quad n = (Z\alpha)^2 p (1 - p)/d^2$$

141 where:

142  $Z\alpha$  = standard normal variate (1.96 for a 95% confidence interval);

143  $p$  = prevalence of HDV among pregnant women in Cameroon (4.0) [9];

144  $d$  = precision of the estimate (0.01).

145 Substituting the figures in the above formula yields 1475.2 (nearest whole number). Thus, a  
146 minimum of 1475 participants was required.

147 Data collection took place in 3 stages. Before enrolling the participants, a group sensitization  
148 at the hospital or Health Center was conducted to raise awareness on hepatitis B transmission  
149 and prevention, hepatitis B and pregnancy, the importance of HBV screening and the purpose  
150 of the study. Thereafter, 1992 subjects who were willing to be part of the study, were  
151 administered a Consent Form, and upon their consent, a questionnaire with open-ended  
152 questions was administered to collect personal and socio-demographic data, their knowledge,  
153 attitude and practices with respect to hepatitis B. Some women who took part in the sensitization  
154 campaign were not enrolled in the study because they had to have the opinion of their partners,  
155 or did not give any reason.

## *PLOS ONE*

156 A consecutive sampling (non-probability sampling) was used to select only pregnant women of  
157 age over 21 years, who gave a written informed consent. In order to avoid any confusion and  
158 to preserve the anonymity of the participants, each participant was assigned a code that allowed  
159 us to link each questionnaire to its corresponding blood specimen, while another Register of the  
160 ANC used only by hospital staff was established to link the subjects to their results. This same  
161 code was used throughout the analysis in the laboratory and the results were linked to the  
162 identity of the subject by the hospital staff and not by the research team.

### 163 **Laboratory procedures**

164 After completing the questionnaire, 5 ml of blood was drawn from 1992 subjects into a tube  
165 containing ethylene-diamine-tetra-acetic acid (EDTA), processed and the plasma tested for  
166 HBsAg, anti-HIV and anti-HCV antibodies using rapid diagnostic tests (RDT, ABON,  
167 Determine HIV1/2 and KHB Diagnostic kit for HIV antibodies 1 + 2) and ELISA (Murex  
168 HBsAg, and Murex HCV Ab), following the manufacturer's instructions. Furthermore, the  
169 HBsAg-positive samples were tested by ELISA for other HBV infection biomarkers: anti-HBs,  
170 anti-HBc, HBeAg, and anti-HBe. Positive and negative plasma controls were run alongside  
171 each test, following the National Testing Algorithms for these viruses in Cameroon.

172 ELISA was performed to detect anti-HDV antibodies in 134 plasma samples using the ETI-  
173 DELTA-IGMK-2 kit (Dia.Pro Diagnostic Bioprobes srl, Italy). Quantification of HDV RNA  
174 (viral RNA load) by real-time qRT-PCR (Eurobioplex HDV Kit, Eurobio Scientific, France)  
175 was performed using 34 anti-HDV positive plasma samples. All serologic results were made  
176 available to the women within two weeks after specimen collection. The rapid test results were  
177 confirmed by two technicians and the samples with borderline results, were further analyzed by  
178 ELISA. On the other hand, plasma HDV RNA load was quantified by qRT-PCR commercial kit that  
179 detects all 8 main genotypes of HDV, with a lower limit of detection of 100IU/mL. Through these  
180 analyses, the subjects that were infected with HBV and/or HDV, were identified. These results  
181 were linked to the reported answers given by each subject in relation to their knowledge on  
182 modes of transmission and prevention of HBV, their attitude towards prevention of HBV  
183 infection such as vaccination and unprotected sex, as well as their practices that predisposes  
184 them to acquiring HBV and/or HDV.

185 All women who tested positive for HBsAg were offered post-test counselling on their status,  
186 modes of hepatitis B transmission, need for testing of close contacts for hepatitis B, and  
187 vaccination of baby within the first twenty four hours of life against hepatitis B. They were then

## **PLOS ONE**

188 referred for clinical evaluation and management to a gastroenterologist, and those who were  
189 negative for HBsAg were advised to get vaccinated if not yet.

### **190 Statistical analysis**

191 Data collected was regularly checked, corrected, recorded and processed using IBM.SPSS.  
192 Statistics.v20 software, while ensuring anonymity with the use of subject registration code.  
193 Frequencies of qualitative data were estimated as means. Using internal negative and positive  
194 controls in each run, a cycle threshold (Ct) of  $\leq 35$  was considered positive, and  $Ct > 35$  and  $\leq$   
195 45 was considered a non-quantifiable positive result. Using a standard curve drawn from  
196 standards provided by the manufacturer, the HDV RNA load was extrapolated to copies/mL  
197 which was then multiplied by a factor (0.18) to convert into IU/mL. The analysis of the  
198 relationship between the prevalence and the different characteristics of the sample was done  
199 by logistic regression. Using the Pearson Chi-2 test, the factors associated with HBV and  
200 HDV infection, were determined with p values  $<0.05$  considered statistically significant. Ten  
201 samples with missing data were not included in the analysis.

### **202 Ethical considerations**

203 The study was conducted in accordance with the fundamental principles of the Declaration of  
204 Helsinki, with administrative and ethical approval from health facilities and laboratories, as  
205 well as the National Ethics Committee for Human Health Research in Cameroon (N°  
206 2018/06/1150/L/CNERSH/SP), respectively. A written informed consent was obtained from all  
207 participants, data was recorded using unique identifiers to ensure confidentiality, and laboratory  
208 results were returned to participants for potential benefits in their clinical management. The  
209 subjects positive for HBsAg antigen were referred to a gastroenterologist and those HBsAg-  
210 negative were advised to be vaccinated if not yet.

### **211 Results**

#### **212 Socio-demographic parameters and Knowledge, Attitude and Practices of pregnant 213 women**

214 Overall, 1992 pregnant women were tested for HBsAg, with a mean age of  $27.53 \pm 5.68$  years.  
215 The average gestational age was  $17 \pm 6$  weeks, with a majority of the women at the second  
216 trimester pregnancy. One thousand nine hundred and thirteen (1913) women have never  
217 received the hepatitis B vaccine, but 56 had received three doses of the vaccine (2.8%) (Table  
218 1). One thousand six hundred and twenty seven (1627) women were screened for the first time

## PLOS ONE

219 for HBsAg during this study (81.7%). In the group of HBsAg-positive women, 53(39.9%)  
220 women were in their first pregnancy, 75 (56.4%) lived with a partner, 37 (27.8%) knew their  
221 partner's hepatitis B status and 5.4% (2/37) of their partners were positive for HBsAg, 15  
222 (11.3%) had already been tattooed or scarified and 21 (15.7%) had a history of surgery.

### 223 **Prevalence of HDV and HBV Infection markers**

224 Of 1992 pregnant women tested for HBsAg, 133 were positive (6.7%) while 9.8% of women  
225 in the third trimester were HBsAg-positive, and 9.9% of them live in the rural area. Of these,  
226 42 samples were positive for anti-HDV antibodies by serology, with 62.5% with detectable  
227 plasma HDV RNA. Meanwhile, rates of 9.0%, 79.7% and 94.0% for HBeAg, anti-HBe and  
228 anti-HBc, respectively, was recorded for the HBsAg-positive specimens. Table 2 shows the  
229 distribution of serological markers of hepatitis B infection (HBeAg, HBeAb and HBcAb) as a  
230 function of the presence of anti-HDV antibodies, indicating that HBeAg was statistically  
231 significantly associated with the presence of anti-HDV antibodies ( $p = 0.008$ ). Two (4.8%)  
232 women were co-infected with HCV, HBV and HDV, and 5 (11.9%) with HIV, HBV and HDV.  
233 However, HBV/HIV and HBV/HCV co-infections were not associated with anti-HDV  
234 positivity in this study. In univariate analysis, neither of HIV nor HCV serologic positivity was  
235 associated statistically significantly with the presence of anti-HDV antibodies (Table 2).

### 236 **Factors associated with hepatitis delta virus infection**

237  
238 Our study shows that 4 women with more than 5 children were positive for anti-HDV  
239 antibodies. In addition, women living with a partner (44.0%) were more exposed than women  
240 living alone (16.4%) to be infected with HDV ( $p=0.001$ ), while 60.0% of women who had been  
241 tattooed or scarified had anti-HDV antibodies ( $p=0.015$ ) (Table 3). Comparing the  
242 seroprevalence of HDV antibodies against biomarkers of HBV infection, there was a  
243 statistically significant difference with the presence of anti-HBc ( $p=0.008$ ), anti-HBe ( $p=0.001$ )  
244 and HBeAg-negative/Anti-HBe+ ( $p=0.005$ ). Of note, the HBeAg-negative/anti-HBe-positive  
245 profile was the most frequently detected amongst those with plasma HDV RNA viral load of  
246 more than log 3.25 (10.000 copies/mL) (Table 4).

247

### 248 **Discussion**

249 We studied the seroprevalence of anti-HDV antibodies and the presence of plasma HDV RNA  
250 in 130 HBsAg-positive samples, detected in a sample of 1992 pregnant women collected  
251 between January 2019 and July 2022 in seven health structures in the Centre Region of



## *PLOS ONE*

252 Cameroon. Overall, we observed a seroprevalence of HBsAg of 6.7%. These results are close  
253 to those obtained by Torimiro et al in 2018 (6.4%) among pregnant women in Yaoundé,  
254 Cameroon [9]. In comparison to other African countries with similar socio-economic and public  
255 health contexts, such as Nigeria, Gabon and Burkina Faso, similar prevalence has been reported  
256 [23, 24]. We also noted that in our study population the prevalence of HBsAg is higher among  
257 pregnant women in rural areas compared to those in urban areas. Other studies conducted in  
258 rural areas in Cameroon, have recorded higher prevalence ranging from 7.5% to 13.7% [25-  
259 27].

260 This moderate to high prevalence of hepatitis B in rural areas in Cameroon could be related to  
261 the low level of knowledge about hepatitis B modes of transmission and prevention, and risk  
262 factors of attitude and practices including idleness and promiscuity. In other words, these are  
263 factors that would favour transmission of HDV. Although the efficacy of the hepatitis B vaccine  
264 has been proven and has been available since 2005 in the Cameroon EPI [28], this study shows  
265 that vaccination coverage remains very low among women of child-bearing age, which  
266 contributes in keeping the pool of index infected sub population on the increase. It is therefore  
267 not unusual to detect the high prevalence of HDV infection in pregnant women in the Centre  
268 Region of Cameroon. Since 1991 when the first study on the prevalence of HDV was conducted  
269 in Cameroon[29], several studies have been carried out in the general population or among  
270 people with particular socio-demographic characteristics such as pygmies. The variations in the  
271 prevalence of anti-HDV antibody ranged from 10.5% to 69% [16, 21, 30-32]. On the other  
272 hand, very few of these studies have focused on pregnant women who are an index for both  
273 horizontal and vertical transmission of HBV and HDV. These studies reported low levels of  
274 anti-HDV antibodies in pregnant women of 2.3-4.0% [9, 29]. These values are low compared  
275 to the rate of 32.3% anti-HDV antibody prevalence which we obtained in our study. This  
276 difference could be due to the fact that the previous studies were conducted in the Yaoundé an  
277 urban area, where there are better living conditions, higher level of education, awareness and  
278 knowledge of hepatitis B compared to the semi-urban and rural areas that were included in our  
279 study. In comparison of anti-HDV antibody rates among pregnant women in other African  
280 countries such as Benin (11.4%), Mauritania (14.7%), Gabon (15.6%), the Central African  
281 Republic (21.4%)[33-36], our result is higher at 32.3%.

282 Our findings show that the number of children, marital status, presence of tattoos or  
283 scarifications and history of surgery are factors associated with the positivity of anti-HDV

## PLOS ONE

284 antibodies. Besombes and colleagues reported in 2020 that individuals with more than 10 sexual  
285 casual partners and those who received injections were most at risk of getting HDV [16].

286 The rates of HBV serological markers in anti-HDV-positive individuals showed that anti-HBc  
287 antibodies and anti-HBe antibodies were statistically associated with anti-HDV positivity in  
288 this study. Similarly, a majority of women with the HBeAg-negative/HBeAb-positive  
289 serological profile, had plasma HDV RNA viral load ranging from 10000 to 35000 copies/mL.

290 Limitations of this study include the performance of the test HDV antibody test kit and the lack  
291 of a national testing algorithm for diagnosis of HDV infection in Cameroon.

### 292 **Conclusion**

293 In conclusion, the results of this study show that in spite of the availability of the hepatitis B  
294 vaccine in the EPI in Cameroon, HBV infection is moderately endemic (6.7%) in the Centre  
295 Region of Cameroon, while HDV rate is 32.3% among pregnant women. Increasing number of  
296 casual sexual partners and high level of HDV viremia, may favour horizontal and vertical co-  
297 transmission of HDV in this population. Hence, the need to intensify awareness and control  
298 strategies for hepatitis B and D among pregnant women and contribute to the global elimination  
299 of hepatitis B.

### 300 **Acknowledgement**

301 We acknowledge the financial and technical contributions from the Chantal Biya International  
302 Reference Centre for Research on Prevention and Management of HIV/AIDS to carry out this  
303 study.

304 **Funding** was provided by the Chantal Biya International Reference Centre for Research on  
305 Prevention and Management of HIV/AIDS (CIRCB). And the WHO Sasakawa 2019 Health  
306 Prize to Judith Torimiro.

307

### 308 **References**

- 309 1. WHO, Key facts on hepatitis B. 2020.
- 310 2. Sawadogo, A., et al., *Seroprevalence of hepatitis D virus infection in a population of*  
311 *blood donors carrying HBs Antigen at the Bobo-Dioulasso Regional Blood Transfusion*  
312 *Center*. Journal Africain d'Hépatogastroentérologie, 2016. **10**(1): p. 31-33.

## PLOS ONE

- 313 3. Sahin, A., et al., *Anti-HDV seroprevalance among patients with previous HBV infection.*  
314 North Clin Istanb, 2018. **5**(2): p. 132-138.
- 315 4. Medhat, A., et al., *Acute viral hepatitis in pregnancy.* Int J Gynaecol Obstet, 1993.  
316 **40**(1): p. 25-31.
- 317 5. Dulger, A.C., et al., *High prevalence of chronic hepatitis D virus infection in Eastern*  
318 *Turkey: urbanization of the disease.* Arch Med Sci, 2016. **12**(2): p. 415-20.
- 319 6. A.T. Kabamba, C.M.M., C.M. Nyembo, B.M. Kabamba Et And A.O. Longanga,  
320 *Hepatitis D seroprevalence among people with chronic hepatitis B in Lubumbashi*  
321 *(DRC).* 2020.
- 322 7. Stockdale, A.J., et al., *Prevalence of hepatitis D virus infection in sub-Saharan Africa:*  
323 *a systematic review and meta-analysis.* Lancet Glob Health, 2017. **5**(10): p. e992-e1003.
- 324 8. Daw, M.A., et al., *The Epidemiology of Hepatitis D Virus in North Africa: A Systematic*  
325 *Review and Meta-Analysis.* ScientificWorldJournal, 2018. **2018**: p. 9312650.
- 326 9. Torimiro, J.N., et al., *Rates of HBV, HCV, HDV and HIV type 1 among pregnant women*  
327 *and HIV type 1 drug resistance-associated mutations in breastfeeding women on*  
328 *antiretroviral therapy.* BMC Pregnancy Childbirth, 2018. **18**(1): p. 504.
- 329 10. WHO, *Key facts on hepatitis D.* 2022.
- 330 11. Zanetti, A.R., et al., *Perinatal transmission of the hepatitis B virus and of the HBV-*  
331 *associated delta agent from mothers to offspring in northern Italy.* J Med Virol, 1982.  
332 **9**(2): p. 139-48.
- 333 12. Huang, Y.H., et al., *Phylogenetic analysis to document a common source of hepatitis D*  
334 *virus infection in a mother and her child.* Zhonghua Yi Xue Za Zhi (Taipei), 1999.  
335 **62**(1): p. 28-32.
- 336 13. Sellier, P., et al., *Untreated highly viraemic pregnant women from Asia or sub-Saharan*  
337 *Africa often transmit hepatitis B virus despite serovaccination to newborns.* Liver Int,  
338 2015. **35**(2): p. 409-16.
- 339 14. Sellier, P.O., et al., *Hepatitis B Virus-Hepatitis D Virus mother-to-child co-*  
340 *transmission: A retrospective study in a developed country.* Liver Int, 2018. **38**(4): p.  
341 611-618.
- 342 15. Yuan, J., et al., *Antepartum immunoprophylaxis of three doses of hepatitis B*  
343 *immunoglobulin is not effective: a single-centre randomized study.* J Viral Hepat, 2006.  
344 **13**(9): p. 597-604.
- 345 16. Besombes, C., et al., *The epidemiology of hepatitis delta virus infection in Cameroon.*  
346 Gut, 2020. **69**(7): p. 1294-1300.

## PLOS ONE

- 347 17. Stockdale, A.J., et al., *The global prevalence of hepatitis D virus infection: Systematic*  
348 *review and meta-analysis*. J Hepatol, 2020. **73**(3): p. 523-532.
- 349 18. Bigna, J.J., et al., *Seroprevalence of hepatitis B virus infection in Cameroon: a*  
350 *systematic review and meta-analysis*. BMJ Open, 2017. **7**(6): p. e015298.
- 351 19. CAMPHIA 2017 population impact assessment of HIV in Cameroon,. 2020.
- 352 20. Directorate for Disease Control, the E.e.I.P.-D., *Monitoring Report on Key Health*  
353 *Indicators in Cameroon in 2019*. 2022.
- 354 21. Butler, E.K., et al., *High prevalence of hepatitis delta virus in Cameroon*. Sci Rep, 2018.  
355 **8**(1): p. 11617.
- 356 22. Pourhoseingholi, M.A., M. Vahedi, and M. Rahimzadeh, *Sample size calculation in*  
357 *medical studies*. Gastroenterol Hepatol Bed Bench, 2013. **6**(1): p. 14-7.
- 358 23. Groc, S., et al., *High prevalence and diversity of hepatitis B and hepatitis delta virus in*  
359 *Gabon*. J Viral Hepat, 2019. **26**(1): p. 170-182.
- 360 24. Lingani, M., et al., *The changing epidemiology of hepatitis B and C infections in*  
361 *Nanoro, rural Burkina Faso: a random sampling survey*. BMC Infect Dis, 2020. **20**(1):  
362 p. 46.
- 363 25. Sone, L.H.E., et al., *Prevalence and Identification of Serum Markers Associated with*  
364 *Vertical Transmission of Hepatitis B in Pregnant Women in Yaounde, Cameroon*. Int J  
365 MCH AIDS, 2017. **6**(1): p. 69-74.
- 366 26. Eyong, E.M., et al., *The prevalence of HBsAg, knowledge and practice of hepatitis B*  
367 *prevention among pregnant women in the Limbe and Muyuka Health Districts of the*  
368 *South West region of Cameroon: a three-year retrospective study*. Pan Afr Med J, 2019.  
369 **32**: p. 122.
- 370 27. Mawouma, A.R.N., et al., *[Factors associated with hepatitis B infection in pregnant*  
371 *women at health facilities in the health district of Mokolo/Far North of Cameroon]*. Pan  
372 Afr Med J, 2022. **41**: p. 61.
- 373 28. Gatchalian, S., et al., *A new DTPw-HBV/Hib vaccine is immunogenic and safe when*  
374 *administered according to the EPI (Expanded Programme for Immunization) schedule*  
375 *and following hepatitis B vaccination at birth*. Hum Vaccin, 2005. **1**(5): p. 198-203.
- 376 29. Ndumbe, P.M., *Hepatitis D in Yaounde, Cameroon*. Apmis, 1991. **99**(2): p. 196-8.
- 377 30. Noubissi-Jouegouo, L., et al., *Evolutionary trends in the prevalence of anti-HDV*  
378 *antibodies among patients positive for HBsAg referred to a national laboratory in*  
379 *Cameroon from 2012 to 2017*. BMC Res Notes, 2019. **12**(1): p. 417.

## PLOS ONE

- 380 31. Luma, H.N., et al., *Prevalence and Characteristics of Hepatitis Delta Virus Infection in*  
381 *a Tertiary Hospital Setting in Cameroon*. J Clin Exp Hepatol, 2017. **7**(4): p. 334-339.
- 382 32. Foupouapouognigni, Y., et al., *Endemicity and genetic diversity of Hepatitis delta virus*  
383 *among Pygmies in Cameroon, Central Africa*. BMC Res Notes, 2022. **15**(1): p. 87.
- 384 33. Mansour, W., et al., *Prevalence, risk factors, and molecular epidemiology of hepatitis*  
385 *B and hepatitis delta virus in pregnant women and in patients in Mauritania*. J Med  
386 Virol, 2012. **84**(8): p. 1186-98.
- 387 34. Makuwa, M., et al., *Prevalence and genetic diversity of hepatitis B and delta viruses in*  
388 *pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8*  
389 *originates from and is endemic in central Africa*. J Clin Microbiol, 2008. **46**(2): p. 754-  
390 6.
- 391 35. Komas, N.P., et al., *Hepatitis B and hepatitis D virus infections in the Central African*  
392 *Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing*  
393 *spread in asymptomatic young adults*. PLoS Negl Trop Dis, 2018. **12**(4): p. e0006377.
- 394 36. De Paschale, M., et al., *Prevalence of HBV, HDV, HCV, and HIV infection during*  
395 *pregnancy in northern Benin*. J Med Virol, 2014. **86**(8): p. 1281-7.

396

**PLOS ONE**

397 **Table 1: Characteristics of the study population**

Variables		HBsAg		p-value
		Negative (%)	Positive (%)	
<b>Age (years)</b> <b>Mean = 27 years</b>	15-20	209 (91.2)	19 (8.8)	0,21
	21-25	580 (92.2)	49 (7.8)	
	26-30	507 (94.9)	27 (5.1)	
	31-35	360 (93.0)	27 (7.0)	
	36-40	172 (94.0)	11 (6.0)	
	41-45	31 (100.0)	0 (0)	
<b>Gestational age (weeks)</b> <b>Mean = 18 weeks</b>	1-14	527(92.1)	45(7.9)	<b>0 .017*</b>
	15-28	940(94.4)	65(5.6)	
	29-42	374(90.1)	41(9.9)	
<b>Hepatitis B vaccination</b>	Not vaccinated	1779(93.04%)	133(7.0)	0.637
	1 Dose	10(100.0%)	0(0)	
	2 Doses	14(100.0%)	0(0)	
	3 Doses	56(0.58%)	0(0)	
<b>Location of health institution/study site</b>	urban	1169(94.88%)	63(5.1)	<b>0 .016*</b>
	semi-urban	263(91.96%)	<b>23(8.0)</b>	
	rural	427(90.08%)	<b>47(9.9)</b>	

398

399 *\*.The Chi-square statistic is significant at the .05 level.*

400

401

**PLOS ONE**

402 **Table 2: Distribution of viral infections (HCV, HDV, and HIV) and serological markers**  
 403 **of hepatitis B infection among HBsAg-positive pregnant women**

Serological markers		Presence of anti-HDV antibodies		
		Negative (%)	Positive (%)	P-value
<b>Anti-HIV</b>	Negative	80(68.4)	37(31.6)	0.612
	Positive	8(61.5)	5(38.46)	
<b>Anti-HCV</b>	Negative	88(68.8)	40(31.2)	0.119
	Positive	0(0)	2(100.0)	
<b>HBeAg</b>	Negative	82(69.5)	36(30.5)	0.169
	Positive	6(50.0)	6(50.0)	
<b>HBc antibodies</b>	Negative	2(25.0)	6(75.0)	<b>0.008*</b>
	Positive	86(70.5)	36(29.5)	
<b>HBe antibodies</b>	Negative	9(36.0)	16(64.0)	<b>0.001*</b>
	Positive	79(75.2)	26(24.8)	
<b>HBeAg-/HBeAb -</b>		8(44.4)	10(55.6)	<b>0.005*</b>
<b>HBeAg+/HBeAb -</b>		0(0)	6(100.0)	
<b>HBeAg-/HBeAb +</b>		75(75.3)	26(25.7)	
<b>HBeAg+/HBeAb +</b>		5(100.0)	0(0)	

404

405 *Note*

406 **+**: positive;

407 **-**: negative;

408 *\*.The Chi-square statistic is significant at the .05 level.*

409

**PLOS ONE**

410 **Table 3: Variation in the prevalence of hepatitis delta according to the clinical**  
 411 **characteristics of pregnant women**

Variable	Presence of anti-HDV antibodies			
	Negative (%)	Positive (%)	p-value	
<b>Age Group (years)</b> Mean = 26 years	15-20	16(84.2)	3 (15.8)	0.50
	21-25	31 (66.0)	16 (34.0)	
	26-30	17 (60.7)	11 (39.3)	
	31-35	18 (69.2)	8 (30.8)	
	36-40	6 (60.0)	4 (40.0)	
<b>Gestational age (weeks)</b> Mean : 22 (weeks)	1-14	18 (69.2)	8 (30.2)	0.92
	15-28	34 (68.0)	16 (32.0)	
	29-42	36 (66.7)	18 (33.3)	
<b>Number of life births</b>	0	40 (75.5)	13 (24.5)	<b>0.030</b>
	1	26 (72.2)	10 (27.8)	
	2	10 (62.5)	6 (37.5)	
	3	11 (55.0)	9 (45.0)	
	4	1 (100.0)	0 (0.0)	
	5+	0 (0.0)	4 (100.0)	
<b>Marital status</b>	life alone	46 (83.6)	9 (16.4)	<b>0.001*</b>
	married life	42 (56.0)	33 (44.0)	
<b>Knowledge of tattoo</b>	yes	6 (40.0)	9 (60.0)	<b>0.015*</b>
	no	82 (71.3)	33 (28.7)	
<b>History of surgical operations</b>	yes	19 (90.5)	2 (9.5)	<b>0.015*</b>
	no	69 (63.3)	40 (36.7)	
<b>Knowledge of female circumcision</b>	yes	5 (100.0)	0 (00.0)	0.115
	no	83 (66.4)	42 (33.6)	
<b>Use of alcohol</b>	yes	39 (68.4)	18 (31.6)	0.87
	no	49 (67.1)	24 (32.9)	
<b>Aware of hepatitis B status of close people</b>	no one knows	2 (100.0)	0 (00.0)	0.189
	husband	15 (60.0)	10 (40.0)	
	family member	0 (00.0)	2 (100.0)	
	friend	46 (64.8)	25 (35.2)	

412

413 *Note*

414 *\*.The Chi-square statistic is significant at the .05 level.*

415



*PLOS ONE*

416 **Table 4: Plasma HDV RNA viral load as a function of the serological profile of HBeAb**  
417 **and HBeAg markers**

Serological profile	HDV RNA viral load (copies/mL)				
	Not detected	< 15	(15-1000)	(1000-10000)	(10000-35000)
<b>HBeAg-/HBeAb -</b>	5(33.33%)	0(0.0%)	2(40.0%)	2(40.0%)	0(0.0%)
<b>HBeAg+/HBeAb -</b>	1(6.67%)	0(0.0%)	1(20.0%)	0(0.0%)	1(20.0%)
<b>HBeAg-/HBeAb +</b>	9(60.0%)	4(100.0%)	2(40.0%)	3(60.0%)	4(80.0%)
<b>Total</b>	15	4	5	5	5

418



**Figure 1: Map of ten regions of Cameroon.**

Figure 1




Figure 2: Diagram showing procedure of screening for HBsAg and antibodies to and RNA of HDV of pregnant women.

Figure 2